Thomas Jefferson University

Jefferson Digital Commons
Department of Molecular Physiology and
Biophysics Faculty Papers

Department of Molecular Physiology and
Biophysics

4-26-2013

Nuclear localization of CPI-17, a protein phosphatase-1 inhibitor
protein, affects histone H3 phosphorylation and corresponds to
proliferation of cancer and smooth muscle cells.
Masumi Eto
Thomas Jefferson University

Jason A Kirkbride
Thomas Jefferson University

Rishika Chugh
Thomas Jefferson University
Follow this and additional works at: https://jdc.jefferson.edu/physfp

Nana Kofi Karikari

Part of
the Biochemistry
Thomas
Jefferson
UniversityCommons, Cell Biology Commons, and the Cellular and Molecular Physiology
Commons

Jee In Kim

Let
us National
knowUniversity
how School
access
to this
you
Kyungpook
of Medicine,
Daegudocument
700-422, Republic benefits
of Korea
Recommended Citation
Eto, Masumi; Kirkbride, Jason A; Chugh, Rishika; Karikari, Nana Kofi; and Kim, Jee In, "Nuclear
localization of CPI-17, a protein phosphatase-1 inhibitor protein, affects histone H3
phosphorylation and corresponds to proliferation of cancer and smooth muscle cells." (2013).
Department of Molecular Physiology and Biophysics Faculty Papers. Paper 11.
https://jdc.jefferson.edu/physfp/11
This Article is brought to you for free and open access by the Jefferson Digital Commons. The Jefferson Digital
Commons is a service of Thomas Jefferson University's Center for Teaching and Learning (CTL). The Commons is
a showcase for Jefferson books and journals, peer-reviewed scholarly publications, unique historical collections
from the University archives, and teaching tools. The Jefferson Digital Commons allows researchers and interested
readers anywhere in the world to learn about and keep up to date with Jefferson scholarship. This article has been
accepted for inclusion in Department of Molecular Physiology and Biophysics Faculty Papers by an authorized
administrator of the Jefferson Digital Commons. For more information, please contact:
JeffersonDigitalCommons@jefferson.edu.

As submitted to:
Biochemical and Biophysical Research Communications
And later published as:
Nuclear localization of CPI-17, a protein phosphatase-1 inhibitor protein,
affects histone H3 phosphorylation and corresponds to proliferation of
cancer and smooth muscle cells.
Volume 434, Issue 1, 26 April 2013, Pages 137-142
DOI: 10.1016/j.bbrc.2013.03.055
Masumi Eto1, Jason A Kirkbride1, Rishika Chugh1, Nana Kofi Karikari1, and Jee In Kim1,2
1

Department of Molecular Physiology and Biophysics, and Kimmel Cancer Center, Thomas Jefferson
University, 1020 Locust Street, Pennsylvania 19107, USA
2
Cardiovascular research institute ,Kyungpook National University School of Medicine, Daegu 700-422,
Republic of Korea
Corresponding to Masumi Eto, phone: 215-503-7891, email: masumi.eto@jefferson.edu
CPI-17 (C-kinase-activated protein phosphatase-1 (PP1) inhibitor, 17kDa) is a cytoplasmic protein
predominantly expressed in mature smooth muscle (SM) that regulates the myosin-associated PP1
holoenzyme (MLCP). Here, we show CPI-17 expression in proliferating cells, such as pancreatic cancer
and hyperplastic SM cells. Immunofluorescence showed that CPI-17 was concentrated in nuclei of
human pancreatic cancer (Panc1) cells. Nuclear accumulation of CPI-17 was also detected in the
proliferating vascular SM cell culture and cells at neointima of rat vascular injury model. The N-terminal
21-residue tail domain of CPI-17 was necessary for the nuclear localization. Phospho-mimetic Aspsubstitution of CPI-17 at Ser12 attenuated the nuclear import. CPI-17 phosphorylated at Ser12 was not
localized at nuclei, suggesting a suppressive role of Ser12 phosphorylation in the nuclear import.
Activated CPI-17 bound to all three isoforms of PP1 catalytic subunit in Panc1 nuclear extracts. CPI-17
knockdown in Panc1 resulted in dephosphorylation of histone H3 at Thr3, Ser10 and Thr11, whereas it
had no effects on the phosphorylation of myosin light chain and merlin, the known targets of MLCP. In
parallel, CPI-17 knockdown suppressed Panc1 proliferation. We propose that CPI-17 accumulated in
the nucleus through the N-terminal tail targets multiple PP1 signaling pathways regulating cell
proliferation.

Abbreviations: PP1, protein phosphatse-1; CPI-17, PKC-activated PP1 inhibitor (Mr=17kDa); MLCP,
myosin light chain phosphatase; MYPT1, myosin phosphatase targeting subunit, GFP, green
fluorescence protein; PKC, protein kinase C; ROCK, RhoA-associated coiled coil kinase.
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INTRODUCTION
Abnormal acceleration in epithelial and mesenchymal cell proliferation is a hallmark of
tumorigenesis and hyperplasia. Protein phosphatase-1 (PP1) is a dominant Ser/Thr phosphatase in
eukaryotic cells, and known to play multiple roles in the regulation of cell proliferation. The catalytic
subunits of PP1 (PP1C), consisting of four isoforms (,   1, and testis-specific 2), are capable
of dephosphorylating a range of cellular proteins. Each PP1C isoform is assembled with a specific
group of polypeptides, known as targeting subunits or interacting proteins, which regulate specific
activity and compartmentalize PP1 at subcellular loci [1,2]. In addition to over 200 PP1 targeting
subunits, 10 polypeptides specifically inhibit cellular PP1 holoenzymes in mammalian cells, classified
into PP1 inhibitor proteins [1,2,3]. Characterization of PP1 targeting subunits and the endogenous
inhibitors that mediate signals regulating cell proliferation is vital to fully understand mechanisms
causing hyperplasia,
CPI-17 was discovered as a specific inhibitor for the myosin light chain phosphatase (MLCP),
consisting of the PP1C () isoform associated with MYPT1, the myosin-targeting subunit. CPI-17 is
highly expressed (at µM levels) in mature smooth muscles (SM) [4]. In mature SM, G-protein-coupled
receptor signals trigger the activation of PKC and ROCK that phosphorylate CPI-17 at Thr38. This
phosphorylation enhances the inhibitory potency of CPI-17 over 1,000-fold, resulting in MLCP inhibition,
and consequent elevation in myosin light chain phosphorylation, causing SM contraction. The CPI-17mediated MLCP regulation plays pivotal roles in adjusting responsiveness of SM contraction to stimuli,
a process known as Ca2+ sensitization [3,5,6]. Accumulating lines of evidence suggest that changes in
CPI-17 levels are associated with impaired excitation-contraction coupling of SM under pathological
conditions, such as hypertension, asthma, gastrointestinal diseases, and urinary tract dysfunctions
(reviewed in [3,7]).
The CPI-17 protein consists of a central four-helix bundle domain sandwiched with intrinsically
unstructured N- and C-terminal tails. The central domain, whose structure is conserved among
members of the CPI-17 family, such as PHI-1, KEPI and GBPI, is necessary and sufficient for the
phosphorylation-dependent inhibition of MLCP [7]. Purified phospho (P)-CPI-17 inhibits MLCP with
IC50 of <10nM and the isolated PP1C with lesser potency (reviewed in [3,7]). The inhibitory
phosphorylation site, Thr38, resides in the loop region adjacent to the four-helix bundle. P-Thr38 in the
loop directly docks at the bi-metal active site of PP1C, causing competitive inhibition [8]. In the MLCP
holoenzyme, MYPT1 contacts both PP1C and CPI-17, stabilizing the enzyme-inhibitor interaction [7,9].
On the other hand, PP1C assembled with other PP1 targeting subunits, such as the glycogen-targeting
subunit, rapidly dephosphorylates P-CPI-17 as a substrate and thereby neutralizes the inhibitory action
[8]. Thus, PP1 targeting subunits determine whether CPI-17 acts as a specific inhibitor or a substrate of
PP1C. What has yet to be fully evaluated is whether P-CPI-17 regulates only MLCP among >200 PP1
holoenzymes in cells.
Upon de-differentiation of SM cells, CPI-17 expression declines to 10% of the level in mature
SM [10,11,12]. It is worth noting that the expression level of CPI-17 in de-differentiated SM cells
remains over 10-fold greater compared to the IC50 with MLCP. Recently, CPI-17 was suggested to
inhibit MLCP in SM cell culture and regulate MEF2C-mediated SM differentiation [13]. Also, it has been
claimed that MLCP is a target of CPI-17 in cancer cells [14]. On the other hand, ectopic CPI-17 protein
expressed in fibroblasts and in SM cell culture accumulates in nuclei [13,15], leaving open the

possibility of CPI-17 regulating PP1 signaling in the nucleus. Here, we determined that CPI-17 is
actively imported into nuclei and regulates histone phosphorylation and cell proliferation.

MATERIALS AND METHODS
Immunofluorescence and immunohistochemistry: Immunofluorescence and immunohistochemistry
were performed as described previously [11,15]. Briefly, cells seeded on fibronectin-coated coverslip
were fixed with 4% paraformaldehyde, and permeabilized with 0.1% Triton X-100, followed by indirect
immunostaining. Paraffin-embedded sections of rat aorta at 14 weeks after balloon-catheter injury (gift
from Dr. Avril V. Somlyo at University of Virginia) were prepared and processed as described previously
[11]. Samples stained without primary antibodies were used as blank (BLK). Fluorescence microscopy
and spot densitometry of digital images were done using the spinning-disk confocal microscope
(Olympus IX70 plus BD CARV-II) with BD IPLab imaging software [11]. Nuclear / cytoplasmic (N/C)
Index was defined as the ratio of staining densities at the nucleus and the cytoplasm of a cell. Mean
values ± SEM of N/C index were obtained from 8-10 cells.
Others: Total protein extracts of human pancreatic cancer cell lines (L3.6pl, AsPC-1 and BxPC-3) and
the 3xGFP tag expression vector were gifts from Drs J. Thomas Persons and Ian Macara at University
of Virginia, respectively. QRTPCR and immunoblotting were done as described previously [12]. Cell
proliferation was assayed in triplicate using Panc1 cells treated with negative control or CPI-17
targeting siRNA. Cells were treated with siRNA for 72 h in the presence of 10% FBS, fixed with dry
methanol, stained with hematoxylin solution (Sigma), and counted under microscope. Mean values ±
SEM of the number of cells were obtained from at least three image fields in each dish. Asterisk in each
figure indicates p<0.05 in Student t-test compared to control. Conditions of cell culture, siRNA
knockdown, transient transfection [12], subcellular fractionation [16] and pulldown assay [8] are
described in Supplemental information. All primary and secondary antibodies used were listed in
Supplemental table 1.

RESULTS
Expression and nuclear localization of CPI-17 in cancer and SM cells: We determined the levels of
CPI-17 mRNA and protein using quantitative RTPCR and immunoblotting (Fig. 1A and B). In QRTPCR
analysis (Fig. 1A), CPI-17 mRNA was especially abundant in pancreatic cancer cells (Panc1),
compared with fibroblasts (HEK293) and other cancer cell lines, such as cervical adenocarcinoma
(HeLa), neuroblastoma (SH-SY5Y), and leiomyosarcoma (SK-LMS1). To estimate CPI-17 protein levels,
extracts of rat aorta tissue and cancer cells (10µg each) were subjected to immunoblotting with antiCPI-17 (Fig. 1B). Actin was stained for loading control. CPI-17 protein was detected in Panc1 cells at
approximately 10% of the level in aorta tissue, but not in the SM-derived LMS1 cells (Fig. 1B, left). The
level in Panc1 cells is equivalent to that of the SM cell culture [10,11]. Among human pancreatic cancer
cell lines (Fig. 1B, right), CPI-17 expression was prominent in Panc1 cells and at lower levels in AsPC-1
and BxPC3 pancreatic cancer cell lines. CPI-17 was also expressed in different derivatives of Panc-1
cells (data not shown). Thus, Panc1 can be a model for studying roles of CPI-17 in proliferating cells.
We examined the subcellular localization of CPI-17 by immunofluorescent microscopy of Panc1
and rat aorta SM cell culture (Fig. 1C), and rat aorta wall cross sections (Fig. 1D). Prominent staining

for CPI-17 was co-localized with Hoechst staining in Panc1 (Fig. 1C top left), whereas no nuclear
staining was detected without the primary antibody as a control for specificity (Fig. 1C, top right).
Release of platelet-derived growth factor and basic fibroblast growth factor converts
contractile/quiescent SM cell at vascular media into the proliferative phenotype, which is mimicked by
the SM cells explanted from tissues. As shown in Fig. 1C (bottom panels), nuclear localization of CPI17 was detected in rat aortic SM cell culture, a well-characterized model of the hyperplastic SM. We
further examined subcellular localization of CPI-17 using an established in vivo model of hyperplastic
SM cells. Physical damage of endothelium of rat aorta triggers proliferation and migration of SM cells,
leading to neointima formation, a model of atherosclerosis and restenosis. We have shown that CPI-17
is downregulated in neointima, compared with the cells at SM layers [11].
Fig. 1D show
immunohistochemistry of paraffin-embedded artery section at 14 week after injury co-stained with antiCPI-17, anti-smooth muscle type (sm)-actin and Hoechst. CPI-17 was detected throughout cells at SM
layers in tunica media. On the other hand, CPI-17 in the cells at neointima was concentrated in nuclei
(Fig. 1D, arrows), which is evident in the merged image of CPI-17 staining with Hoechst staining (right
panel). These cells at neointima also expressed sm-actin that was excluded from nuclei (Fig. 1D).
These results suggest that CPI-17 nuclear localization occurs when it is expressed in cells with the
proliferative phenotype.
Mechanisms underlying CPI-17 nuclear localization: The molecular basis of CPI-17 nuclear localization
was investigated using COS1 cells transiently expressing triple-GFP (3xGFP) tagged protein (Fig. 2AL). To mimic the modest level of the endogenous protein, expression of 3xGFP protein was limited to
minimum, and visualized by immunofluorescence using anti-GFP antibody. Intrinsic GFP fluorescence
images of live and fixed cells under epifluorescence are shown in Supplemental figure 1. In the
confocal images, ectopic 3xGFP protein alone (“empty”) was excluded from nuclei due to the size
(Mr=78kDa) (Fig. 2, panel B, G). We quantified staining intensities of the proteins in regions of the
nucleus and the cytoplasm by spot densitometry. The ratio of nuclear staining to cytoplasmic staining
(“N/C Index”) was below 0.5 (panel L), indicating the exclusion of 3xGFP protein from the nucleus (Fig.
2L, “Empty”). By sharp contrast, 3xGFP protein fused with CPI-17 wild type (WT) was accumulated in
nuclei (panel C, H) with N/C Index of over 1.5 (panel L). As shown in Fig. 2A, the N-terminal tail of CPI17 forms a basic-residue cluster, similar to nuclear import signal [17]. Indeed, the deletion of the Nterminal 21-residue eliminated the nuclear accumulation of CPI-17 (Fig. 2D, I, L: 3xGFP-CPI-17(∆N)),
suggesting a functional nuclear localization signal (NLS) in the unstructured N-terminal tail. Purified
kinases, such as PKC, ZIPK, ROCK and ILK, can phosphorylate CPI-17 at Ser12 in the middle of the
N-terminal NLS region (Fig. 2A, marked by dot) [7]. Asp-substitution mimicking the phosphorylation at
Ser12 (3xGFP-CPI-17(S12D)) diminished the nuclear localization (Fig. 2F, K, L), whereas Alasubstitution at Ser12 had no effect (Fig. 2E, J, L).
To determine roles of Ser12 phosphorylation in the nuclear localization, we developed the
antibody recognizing P-Ser12, but not P-Thr38 (Supplemental figure 2). To confirm Ser12
phosphorylation in cells, HEK293 cells expressing HA-tagged CPI-17 was stimulated with phorbol ester
(PMA) and subjected to immunoblotting (Fig. 2M). CPI-17 phosphorylated at Ser12 was detected in the
cell lysates of the quiescent cells, and cells stimulated with PMA at slightly higher level (Fig.2M). Thr38
phosphorylation was enhanced in response to PMA stimulation, as we reported previously [10]. Rat
fundus SM cells expressing higher level of endogenous CPI-17 were fixed with 10% TCA and subjected
to co-immunostaining with the anti-P-S12-CPI-17 antibody plus anti-total CPI-17 and Hoechst (Fig. 2N-

T). Unlike total CPI-17 staining (panel N), P-Ser12-CPI-17 staining (panel O) did not show any nuclear
accumulation with N/C index of around 1.0 (panel T), indicating free diffusion in the cells. On the other
hand, cells stained without primary antibodies (panel Q, R, S) did not show any background signal
under the condition. These results suggest that the phosphorylation of CPI-17 at the N-terminal tail is
sufficient to attenuate the NLS activity.
CPI-17 regulates phosphorylation of nuclear proteins and cell proliferation: We questioned what was
the target of nuclear CPI-17. As shown in Fig. 3A, the sequential extraction of Panc1 cells showed that
majority of MYPT1 existed in the soluble fraction, which is consistent with the report by Murata et al [18].
A small amount of MYPT1 was extracted from nuclei along with Sp1 protein a marker of nuclear
proteins (Fig. 3A). This is consistent with the data in proteomics that showed MYPT1 in nuclear extracts,
in addition to approximately 20 other PP1-binding polypeptides [19,20]. The soluble fraction and
nuclear extracts were subjected to a CPI-17 pulldown assay (Fig. 3A, B). Both MYPT1 and PP1C in the
soluble fraction bound to tP-CPI-17-beads, but not to unphosphorylated (U)-CPI-17 or blank beads
(BLK), demonstrating the phosphorylation-dependent binding of CPI-17 to the MYPT1-PP1C complex
(Fig. 3A). MYPT1 in the nuclear extracts failed to bind tP-CPI-17 beads (Fig. 3A), although tP-CPI-17
bound to all isoforms of PP1C, (, , and 1) in nuclear extracts (Fig. 3B). Because most nuclear PP1
targeting subunits recognize specific PP1C isoforms, CPI-17 likely binds multiple types of nuclear PP1
holoenzymes in nuclei.
We determined phosphorylation of established substrate proteins for MLCP in Panc1 cells after
CPI-17 knockdown (Fig. 4). siRNA knockdown effectively eliminated CPI-17 protein without changing
the expression of PP1C isoforms (Fig. 4A, left). Remarkably, the phosphorylation of myosin light chain
(LC20), merlin (MLN) and ezrin/radixin/moesin (ERM), the major substrates of MLCP, did not change in
response to CPI-17 knockdown (Fig. 4A, right). On the other hand, CPI-17 knockdown resulted in the
net de-phosphorylation of histone H3 at Thr3 (P-H3T3), at Ser10 (P-H3S10) and at Thr11 (P-H3T11)
(Fig. 4A, right). As shown in Fig. 4B, after a 72-h treatment with control siRNA, the number of Panc1
cells increased 2.5-fold, whereas CPI-17 knockdown resulted in a 40 % reduction in Panc1 proliferation.
These results suggest that CPI-17 in the nucleus inhibits a subset of PP1 responsible for
dephosphorylation of histone H3, upregulating cell proliferation signaling.

DISCUSSION
In this report we present evidence suggesting that CPI-17 regulates nuclear PP1 signaling
pathways. Based on the model established in mature SM tissues [3,7,21], CPI-17 was anticipated to
inhibit MLCP in cancer cells, amplifying Ras signaling through merlin phosphorylation [14], and in
vascular SM cell culture, regulating MEF2C and the differentiation [13]. By sharp contrast, our finding
shows that CPI-17 inhibits nuclear PP1 responsible for histone H3 dephosphorylation. The suppression
of Panc1 proliferation by CPI-17 knockdown may be attributed to the histone H3 dephosphorylation,
because the temporal phosphorylation is required for chromatin remodeling during the cell cycle.
MYPT1 possesses an active NLS at the N-terminal domain and is detected in nuclear extracts [20,22].
Clearly, MYPT1 in nuclei is not accessible for CPI-17. We presume that MYPT1 in the nucleus is not in
complex with PP1C [23], otherwise it would have bound to tP-CPI-17. Or, unknown posttranslational
modifications of MYPT1 interfere CPI-17 binding. Over 20 polypeptides in nuclei are found to bind
PP1C, and each of them is a potential target of P-CPI-17 [19,20]. CPI-17 is involved in the

phosphorylation of at least histone H3 Thr3, Ser10 and Thr11, offering a clue to find PP1 holoenzymes
regulated by nuclear CPI-17. Of particular interest, Repo-Man-PP1C is known to dephosphorylate
histone H3 at Thr3, and a candidate of a CPI-17 target [24]. P-histone H3 Ser10 and Thr11 are also
dephosphorylated by PP1, but the targeting subunit remains unknown [24]. Further systematic
investigation is necessary for elucidating nuclear PP1 signaling regulated by CPI-17 in hyperplastic
cancer and SM cells.
The nuclear localization of CPI-17 in proliferating cells, but not in mature SM, was confirmed by
fluorescent microscopy of endogenous proteins and ectopic 3xGFP-proteins. The N-terminal 21-residue
tail, whose sequence is identical in mouse, pig and human, was mapped as the region required for
nuclear localization. This is consistent to our previous finding that FLAG-tagged CPI-17(1-120) and (189) proteins are accumulated in nuclei of rat embryo fibroblasts [15]. We presume that the binding of
importin complex to the N-terminal tail drives the nuclear import of CPI-17. This active nuclear import of
CPI-17 is neutralized upon Ser12 phosphorylation, based on the data using the phospho-mimetic S12D
protein and the phospho-specific antibody. Once CPI-17 is phosphorylated at Ser12, it is diffused but
not excluded from nuclei, suggesting that nuclear export of CPI-17 is driven by diffusion, but not
through active exporting mechanisms, such as CRM1 signaling. 3xGFP-CPI-17(∆N) and (S12D) was
excluded from nuclei, because of the size (>78kDa). It has known that PKC, ZIPK, ROCK and ILK, are
capable of the phosphorylation of CPI-17 at Thr38 as well as Ser12 [7]. Our data here suggest that
Ser12 phosphorylation occurs in cells. In addition, there are two more Ser residues (Ser16 and Ser18)
in the N-terminal tail of CPI-17, which may play an inhibitory role in the nuclear import. It is possible that
pathological stresses alter the phosphorylation state at the N-terminal NLS of CPI-17 regulating the
subcellular distribution of the signaling. Identification of the kinases phosphorylating at Ser12 and
adjacent sites will be a next step toward establishing pathological links between the redistribution of
CPI-17 signaling and hyperplastic phenotype.
In addition to CPI-17, other endogenous PP1 inhibitors are known to undergo nuclear shuttling,
in response to environmental changes. PP1 inhibitor-2 is redistributed from the nucleus to the
cytoplasm, when the cell-cell contact is established [16]. Another soluble PP1 inhibitor, DARPP32, is
actively imported into nuclei in response to amphetamine and cocaine treatments due to the
phosphorylation at Ser97, resulting in the elevation in histone H3 Ser10 phosphorylation [25]. Nuclear
shuttling of PP1 inhibitors may be a mechanism by which mammalian cells adjust phosphorylation
levels in the nucleus in response to environmental changes.

REFERENCES
[1]
Cohen, P.T., Protein phosphatase 1--targeted in many directions, J. Cell Sci. 115 (2002) 241256.
[2]
Bollen, M., Peti, W., Ragusa, M.J., Beullens, M., The extended PP1 toolkit: Designed to create
specificity, Trends Biochem. Sci. 35 (2011) 450-458.
[3]
Eto, M., Brautigan, D.L., Endogenous inhibitor proteins that connect Ser/Thr kinases and
phosphatases in cell signaling, IUBMB Life 64 (2012) scope.
[4]
Woodsome, T.P., Eto, M., Everett, A., Brautigan, D.L., Kitazawa, T., Expression of CPI-17 and
myosin phosphatase correlates with Ca2+ sensitivity of protein kinase C-induced contraction in
rabbit smooth muscle, J. Physiol. 535 (2001) 553-564.
[5]
Kitazawa, T., Masuo, M., Somlyo, A.P., G protein-mediated inhibition of myosin light-chain
phosphatase in vascular smooth muscle, Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 9307-9910.
[6]
Kitazawa, T., Kitazawa, K., Size-dependent heterogeneity of contractile Ca2+ sensitization in rat
arterial smooth muscle, J. Physiol. 590 (2012) 5401-5423.
[7]
Eto, M., Regulation of cellular protein phosphatase-1 (PP1) by phosphorylation of the CPI-17
family, C-kinase-activated PP1 inhibitors, J. Biol. Chem. 284 (2009) 35273-35277.
[8]
Eto, M., Kitazawa, T., Brautigan, D.L., Phosphoprotein inhibitor CPI-17 specificity depends on
allosteric regulation of protein phosphatase-1 by regulatory subunits, Proc. Natl. Acad. Sci. U. S.
A. 101 (2004) 8888-8893.
[9]
Eto, M., Kitazawa, T., Matsuzawa, F., Aikawa, S., Kirkbride, J.A., Isozumi, N., Nishimura, Y.,
Brautigan, D.L., Ohki, S.Y., Phosphorylation-induced conformational switching of CPI-17
produces a potent myosin phosphatase inhibitor, Structure 15 (2007) 1591-1602.
[10]
Woodsome, T.P., Polzin, A., Kitazawa, K., Eto, M., Kitazawa, T., Agonist- and depolarizationinduced signals for myosin light chain phosphorylation and force generation of cultured vascular
smooth muscle cells, J. Cell Sci. 119 (2006) 1769-1780.
[11]
Kim, J.I., Young, G.D., Jin, L., Somlyo, A.V., Eto, M., Expression of CPI-17 in smooth muscle
during embryonic development and in neointimal lesion formation, Histochem. Cell Biol. 132
(2009) 191-198.
[12]
Kim, J.I., Urban, M., Young, G.D., Eto, M., Reciprocal regulation controlling the expression of
CPI-17, a specific inhibitor protein for the myosin light chain phosphatase in vascular smooth
muscle cells, Am. J. Physiol. Cell Physiol. 303 (2012) C58-68.
[13]
Pagiatakis, C., Gordon, J.W., Ehyai, S., McDermott, J.C., A novel RhoA/ROCK-CPI-17-MEF2C
signaling pathway regulates vascular smooth muscle cell gene expression, J. Biol. Chem. 287
(2012) 8361-8370.
[14]
Jin, H., Sperka, T., Herrlich, P., Morrison, H., Tumorigenic transformation by CPI-17 through
inhibition of a merlin phosphatase, Nature 442 (2006) 576-579.
[15]
Hayashi, Y., Senba, S., Yazawa, M., Brautigan, D.L., Eto, M., Defining the Structural
Determinants and a Potential Mechanism for Inhibition of Myosin Phosphatase by the Protein
Kinase C-potentiated Inhibitor Protein of 17 kDa, J. Biol. Chem. 276 (2001) 39858-39863.
[16]
Leach, C., Eto, M., Brautigan, D.L., Domains of type 1 protein phosphatase inhibitor-2 required
for nuclear and cytoplasmic localization in response to cell-cell contact, J. Cell Sci. 115 (2002)
3739-3745.
[17]
Marfori, M., Mynott, A., Ellis, J.J., Mehdi, A.M., Saunders, N.F., Curmi, P.M., Forwood, J.K.,
Boden, M., Kobe, B., Molecular basis for specificity of nuclear import and prediction of nuclear
localization, Biochim. Biophys. Acta 1813 (2011) 1562-1577.
[18]
Murata, K., Hirano, K., Villa-Moruzzi, E., Hartshorne, D.J., Brautigan, D.L., Differential
localization of myosin and myosin phosphatase subunits in smooth muscle cells and migrating
fibroblasts, Mol. Biol. Cell 8 (1997) 663-673.
[19]
Trinkle-Mulcahy, L., Andersen, J., Lam, Y.W., Moorhead, G., Mann, M., Lamond, A.I., RepoMan recruits PP1 gamma to chromatin and is essential for cell viability, J. Cell Biol. 172 (2006)
679-692.

[20]

[21]
[22]
[23]

[24]

[25]

Moorhead, G.B., Trinkle-Mulcahy, L., Nimick, M., De Wever, V., Campbell, D.G., Gourlay, R.,
Lam, Y.W., Lamond, A.I., Displacement affinity chromatography of protein phosphatase one
(PP1) complexes, BMC Biochem. 9 (2008) 28.
Dimopoulos, G.J., Semba, S., Kitazawa, K., Eto, M., Kitazawa, T., Ca2+-dependent rapid Ca2+
sensitization of contraction in arterial smooth muscle, Circ. Res. 100 (2007) 121-129.
Wu, Y., Muranyi, A., Erdodi, F., Hartshorne, D.J., Localization of myosin phosphatase target
subunit and its mutants, J. Muscle Res. Cell Motil. 26 (2005) 123-134.
Eto, M., Kirkbride, J.A., Brautigan, D.L., Assembly of MYPT1 with protein phosphatase-1 in
fibroblasts redirects localization and reorganizes the actin cytoskeleton, Cell Motil. Cytoskeleton
62 (2005) 100-109.
Qian, J., Lesage, B., Beullens, M., Van Eynde, A., Bollen, M., PP1/Repo-man dephosphorylates
mitotic histone H3 at T3 and regulates chromosomal aurora B targeting, Curr. Biol. 21 (2011)
766-773.
Stipanovich, A., Valjent, E., Matamales, M., Nishi, A., Ahn, J.H., Maroteaux, M., BertranGonzalez, J., Brami-Cherrier, K., Enslen, H., Corbill√à, A.G., Filhol, O., Nairn, A.C., Greengard,
P., Herv √ à, D., Girault, J.A., A phosphatase cascade by which rewarding stimuli control
nucleosomal response, Nature 453 (2008) 879-884.

FIGURE LEGEND
Fig. 1: Expression and localization of CPI-17 in Panc1 cells. (A) QRTPCR for CPI-17 mRNA.
Total RNA (200ng) of the cells indicated was subjected to QRTPCR analysis. Extent of CPI-17 mRNA
was normalized against lamin B, and the value of HEK293 was set as 1.0. (B) Immunoblotting of CPI17 and actin using aorta tissue and cancer cell lysates. Total protein extracts (10µg) were subjected to
immunoblotting. The expression of CPI-17 in human pancreatic cancer cells (right panel) was
visualized with longer exposure (“Longer exp.”), compared with left panel. HEK293; embryonic
fibroblasts, HeLa; cervical adenocarcinoma, SH-SY5Y, neuroblastoma, SK-LMS1; leiomyosarcoma,
and Panc1, L3.6pl, AsPC-1, BxPC-3; pancreatic cancers. (C) Immunofluorescence of Panc1 (top) and
rat aorta SM cells (bottom) using anti-CPI-17 antibody. Proliferating cells were fixed and stained with or
without anti-CPI-17 antibody. Control experiment was carried out without primary antibody (right).
Scale bar, 10µm. (D) Representing images of immunohistochemistry of rat aorta cross section with
neointimal plaques. At 14-days after balloon-catheter injury, rat aorta was subjected to fixation and
sectioning. Sections were co-stained with anti-CPI-17, anti-actin and Hoechst dye. From top to
bottom: lumen (indicated with ** in top left), neointima, SM layers. Right panels show merged image of
anti-CPI-17 staining with Hoechst staining. Bottom panels show the boxed area indicated in the panels
above, respectively. Arrows indicate cells showing prominent nuclear staining with anti-CPI-17. Scale
bar, 10µm.
Fig. 2: Mechanisms underlying nuclear localization of CPI-17. (A) Amino acid sequence of CPI-17
at the N-terminal tail. Arg, Lys and Ser are indicated in bold and underline respectively. (B-L)
Localization of 3xGFP proteins. Rat aorta SM cells were transfected with the vectors encoding 3xGFP
(B, G), 3xGFP-CPI-17(WT) (C, H), ∆N lacking the N-terminal 21 residues (D, I), S12A (E, J), and S12D
(F, K), and visualized by immunofluorescence using anti-GFP. Bar indicates 10µm. N/C Index was
obtained from 8-10 cells. *, p<0.05 compared to “Empty”. (M) CPI-17 phosphorylation at Ser12 in
HEK293 cells. HA-tagged CPI-17 was expressed in HEK293 cells for 24 h. The transfected cells were
harvested for 24 h without serum, followed by the stimulation for 10 min with 1 µM PMA, and subjected
to immunoblotting using anti-P-S12-CPI-17. Total CPI-17 was detected using anti-HA antibody. (N-T)
Localization of phospho-CPI-17 at Ser12 in rat fundus SM cells. TCA-fixed proliferating rat fundus SM
cells were subjected to immunoblotting with anti-total CPI-17 (N) plus anti-P-S12-CPI-17 (O) or without
primary antibodies (Q, R). Scale bar, 10µm. N/C index of P-S12-CPI-17 and total CPI-17 staining was
obtained from 5 independent cells. *, p<0.05, compared to total CPI-17 staining.
Fig. 3: Binding of CPI-17 to nuclear PP1 in Panc1 cells. (A) Differential extraction and CPI-17
pulldown assay. Proliferating Panc1 cells were subjected to sequential extraction as described in
Supplemental information (INPUT). Aliquot of the soluble fraction and the nuclear extracts were mixed
with beads conjugated with unphosphorylated (U)-, tP-CPI-17 and no protein (BLK) and the bound
proteins were analyzed by immunoblotting with antibodies indicated. Sp1 was used as a marker of
nuclear protein. Anti-pan-PP1C antibody recognizes all isoforms. (B) Specificity of CPI-17 binding to
PP1 isoforms. PP1 isoforms bound to tP-CPI-17-beads were determined using antibodies recognizing
the isoforms. Nuc. Ext.: input sample.

Fig. 4. Effects of CPI-17 knockdown on PP1 signaling in Panc1 cells. (A) Panc1 cells were
transfected for 72 h with siRNA for CPI-17 (right lane) or non-targeting control (left lane, Ctl), and
subjected to immunoblotting using antibodies against proteins indicated. P denotes phosphorylated
protein. MLN; merlin, ERM; ezrin/radixin/moesin, H3; histone H3. (B) Effects of CPI-17 knockdown on
cell proliferation. After 72-h knockdown, cells were stained with hematoxylin, and the number of cells
was counted under microscope. The cell number before the knockdown was set as 1.0. n=3, * p<0.05
(Student’s t-test).
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Supplemental information
Material and Methods
Cell culture: The primary SM cells from rat aorta (AoSMC) and stomach fundus (SFSMC) were
prepared using the enzymatic method, and harvested with 1:1 mixture of Dulbecco’s Modified Eagle
Medium (DMEM) and Ham’s F12 supplemented with 10 % fetal bovine serum (FBS), as described
previously [1]. Established cell lines of fibroblasts (HEK293 and COS1), cervical adenocarcinima
(HeLa), neuroblastoma (SH-SY5Y), pancreatic carcinoma (Panc1), and leiomyosarcoma (SK-LMS-1)
were purchased from ATCC. Immortalized cells were harvested with DMEM-10% FBS. Transfection of
COS1 and SK-LMS-1 with the plasmid DNA and Panc1 with siRNA were performed using Xtremegene
HP (Roche) and Lipofectamine RNAiMAX (Invitrogen), respectively.
Others: Total RNA was prepared from the cells harvested in the growth medium in the presence of
10 % FBS using Qiagen RNeasy total RNA preparation kit. QRTPCR was performed in triplicate with
200ng of total RNA and Brilliant II QRTPCR master mix kit with SyBr Green (Stratagene) using
Mx3005P instrument. The relative extent of mRNA was obtained by ∆∆Ct method using the value of
lamin B mRNA and the extent in HEK293 sample as standards [1] [2]. The siRNA duplex targeting
human CPI-17 mRNA 3’-noncoding region (GCUUGCUUGUGUAUAAGUUUU), siGENOME
SMARTpool for CPI-17, and non-targeting control were obtained from ThermoScientific. There was no
significant difference in the results with two siRNA sets (data not shown). Subcellular fractionation was
performed using Panc1 cells in 2x 10cm dishes. First Panc1 cells were homogenized using a dounce
homogenizer with 1 mL of the cytosolic extraction buffer consists of 10mM HEPES, 3mM MgCl 2, 10%
sucrose, 0.5mM TCEP, and 4mM Pefabloc™, pH7.2, and centrifuged for at 700 xg and 4 °C. The
supernatant was used as “the soluble fraction”. The pellet was re-homogenized with 0.5mL of the
nuclear extraction buffer including the cytosolic extraction buffer supplemented with 0.4M NaCl, 1%
Triton X-100, 10% glycerol, and 20 U of DNase I. After 15-min incubation on ice, the nuclear lysates
were re-centrifuged for 16 min at 12,000rpm and 4°C, and the supernatant was used as “nuclear
extracts” [3]. Each the soluble fraction and the nuclear extracts was split into three portions, and mixed
at 4 °C with 15 µL of S-protein-agarose™ (Novagen) plus 1) none (BLK), and 20 µg of 2)
unphosphorylated or 3) thiophosphorylated H6S-tagged CPI-17. After 4-h incubation the beads were
washed 3 times with 0.5 mL of the washing buffer (0.1 M NaCl, 50 mM MOPS-NaOH (pH 7.0), 1 mM
EGTA, 0.1 % Tween 20, 5 % Glycerol, 0.5mM TCEP, and 4mM Pefabloc™), and the bound proteins
were dissociated for 5 min at 100 °C with 50 µL of 2x Laemmli buffer. The solution was subjected to
immunoblotting and the bound proteins were visualized using Supersignal WestPico
chemiluminescence reagent [4].

Supplemental table 1: List of antibodies and a probe used in this work.
Antibody
Primary antibodies
Anti-CPI-17
Anti-pan-actin
Anti-MYPT1
Anti-pan PP1C
Anti-PP1Ca
Anti-PP1Cd
Anti-PP1g1
Anti-2P-T18/S19 LC20
Anti-P-S518-merlin
Anti-P-T3-histone H3
Anti-P-S10-histone H3
Anti-retinoblastoma protein (Rb)
Anti-sm-actin
Anti-GFP
Anti-P-T38-CPI-17
Anti-P-S12-CPI-17*
Anti-HA
Secondary antibodies
Anti-rabbit IgG-AF594
Anti-chicken IgY-AF594
Anti-rabbit IgG-OG488
Anti-rabbit IgG-HRP
Anti-chicken IgY-HRP
Anti-mouse IgG-HRP

Host

Source

Rabbit
Rabbit
Mouse
Chicken IgY
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Rabbit
Mouse
Mouse
Chicken IgY
Chicken IgY
Chicken IgY
Mouse

Custom production by Cocalico Biol Inc, affinity purified [5]
Sigma-Aldrich #A2066
BD Biosciences #612164
Custom production and affinity purified at Aves Lab. Inc [6]
Custom production by QCB, affinity purified [6]
Custom production by QCB, affinity purified [6]
Calbiochem #539543
Cell Signaling Tech. #3674
Abcam #ab115687
Cell Signaling Tech. #9714
Cell Signaling Tech. #9701
Cell Signaling Tech. #9309
Sigma-Aldrich #A2547
Aves Lab #GFP-1010
Custom production and affinity purified at Aves Lab. Inc [7]
Custom production and affinity purified at Aves Lab. Inc
Purified IgG of 12CA5 clone [6]

Goat
Goat
Goat
Goat
Goat
Goat

Molecular Probes #A-11037
Molecular Probes #A-11042
Molecular Probes #)-11038
Jackson Immuno Lab #111-035-144
Jackson Immuno Lab #103-035-155
Jackson Immuno Lab #115-035-166

* The chicken phospho-Ser12-specific CPI-17 IgY was prepared using a synthetic peptide
(CZLGKRVLS(p)KLQSPSR) as antigen (Aves Labs). The specific antibody was purified using the affinity resin
conjugated with the phospho-peptide, followed by the absorption of non-specific fractions using the resin
conjugated with recombinant CPI-17.

Supplemental figure 1: Fluorescence microscopy of 3xGFP protein expressed in COS1
cells.

Supplemental figure 2: Specificity of anti-P-S12-CPI-17.
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